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Cutaneous features with respect to lesion morphology,
location, and time of onset following transplantation were
collected for each patient and further stratiﬁed by aGVHD
clinical grade.
Results: For all cutaneous aGVHD patients (n¼37), the onset
of rash was on average, day +45 (range +4 to +153). The most
common skin lesion morphology was morbilliform (55%)
followed by patchy erythema (38%). Follicular accentuation
was seen in 29% of rashes. The cutaneous eruptions most
commonly occurred on the trunk (69%), arms/legs (67%), face
(62%), ears (38%) and palms (38%).
Comparing grade I and II skin aGVHD patients, grade I
patients (n¼11) had more patchy erythema (73% vs 23%,P ¼
.008), purpuric/violaceous lesions (55% vs 15%,P ¼ .038) or
a reticular pattern (36% vs 0%,P ¼ .005) than grade II patients
(n¼26). Grade II aGVHD patients were found to have cuta-
neous eruptions located more often on the trunk (85% vs
36%,P ¼ .006) and arms/legs (77% vs 36%,P ¼ .028) when
compared to grade I aGVHD patients. Comparison to grade III
(n¼3) and IV (n¼2) aGVHD patients was not performed given
the paucity of cases.
Conclusion: We proﬁled the salient cutaneous features
associated with aGVHD and their relative incidences based
on clinical grade, skin lesion morphology and anatomic site
of involvement. Application of this analysis will allow for
improvements in the diagnosis of aGVHD and differentiation
from other clinical mimickers. Differences in lesional
morphology and location may differentiate grade I and II
cutaneous aGVHD and serve to guide appropriate treatment.427
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Background: Lipoxins (derived from arachidonic acid) and
the resolvins and protectins (derived from u3-poly-
unsaturated fatty acids (PUFAs)) are endogenously produced
lipid mediators with potent anti-inﬂammatory and tissue
healing properties. Acetylsalicylic acid (ASA, aspirin) results
in the synthesis of aspirin-triggered lipoxins, isomers for
these lipid mediators with identical anti-inﬂammatory
actions. In part, these lipid mediators act through down-
regulation of Th1 cytokines known to be important in aGVHD
pathogenesis. The C56BL/6/(C57BL/6 x DBA/2)F1-hybrid is
a major histocompatibility mismatched mouse model of
lethal aGVHD (similar to a non T-cell depleted HLA hap-
loidentical BMT without GVHD prophylaxis) that allows
isolation of the aGVHD effect. We wanted to test whether
these novel lipid mediators could attenuate aGVHD in this
highly inﬂammatory allogeneic transplant mouse model.
Methods: Mice were transplanted according to standard
protocols. Four diets were created, including a control diet
containing 2% u6-PUFAs; and three experimental diets,
enriched for (1) 2%u3-PUFAs (2) 2%u6-PUFAs plus ASA (0.02
mg/g of feed) (3) 2%u3-PUFAs plus ASA. Micewere randomly
fed one diet (n¼10-12 per group) for 8-weeks beforetransplant and the same diet after transplant. A separate
experiment conﬁrmed that feeding the different diets for 8-
weeks before transplant resulted in differential tissue (liver)
stores of u6- and u3-PUFAs. A ﬁfth group (n¼10) was fed the
control diet but injected with the aspirin-triggered lipoxin
15-epi-LxA4 IV on day 0 and IP on day 7 (200 mcg/kg/dose).
The primary outcome was days before the onset of aGVHD-
associated morbidity (humane end point) post-transplant.
Results: Control GVH mice met the humane end-point for
euthanasia as result of aGVHD at a median of 14 days post-
transplant (range: 9-16 days). Kaplan-Meier survival curves
showed modest but statistically signiﬁcant improvements in
survival for mice fed a diet enriched for u3-PUFAs plus ASA
(P¼ .0117) andmice receiving the aspirin-triggered lipoxin (P
¼ .034) compared to the control group. Survival improve-
ments and the onset of lethal aGVHD were delayed by
a matter of days for the mice receiving the interventions.
Conclusion: We provide proof-of-principle that dietary u3-
PUFAs, aspirin, and aspirin-triggered lipoxinsmay offer novel
ways to counteract aGVHD. Our interventions approximate
acceptable human dietary intake for u3-PUFAs and taking
a baby-aspirin once per day. Further experiments using
different aGVHD mouse models are planned.428
An Immunological Assessment of Cytokine Proﬁle of
CD4+ Cells in Patients with Chronic Graft vs Host Disease
(cGVHD) Undergoing Extracorporal Photopheresis (ECP)
Jignesh Dalal 1, Thomas Yankee 2, Ashraf Hassballah 3,
Anne Hirner 4, Robin Ryan 5, Siddhartha Ganguly 6,
Joseph P. McGuirk 7, Sunil Abhyankar 8. 1 BMT, Children's Mercy
Hospital, Kansas City, MO; 2Microbiology and Immunology,
University of Kansas Medical Center, KS; 3 University of Kansas
Medical Center, KS; 4 Apheresis, University of Kansas Hospital,
Kansas City, MO; 5 Children's Mercy Hospital; 6 BMT Program/
Division of Hematology-Oncology, University of Kansas Medical
Center, Westwood, KS; 7 Kansas University Med Ctr MS 5003,
Westwood, KS; 8 Blood and Marrow Transplant, University of
Kansas Medical Center, Westwood, KS
CGVHD develops in more than 50% of survivors of allogeneic
stem cell transplantation and is responsible for mortality in
one third of patients. Long term immunosuppressive therapy
with steroids is the standard treatment. ECP has shown
activity in acute and cGVHD and is successful in about 50% of
the patients after 3 e 6 months of therapy. We studied the
cytokine proﬁles in 6 patients with cGVHD undergoing ECP. A
comprehensive assessment of organ system involvement
using NIH Consensus response assessment tools was done at
study entry and at six months. Patients underwent ECP
treatments twice on two consecutive days every two weeks
for 3 to 6 months. All patients underwent baseline, two-
months, four months and six-month assessments. 10 ml of
leukopheresed blood was obtained from the ECP machine
prior to the initiation of ECP at baseline, and at 2, 4 and 6
months post treatment to assess peripheral blood B and T
cells and the cytokine analysis. CD4+ T cells were puriﬁed
from PBMCs and stimulated with anti-CD3 and anti-CD28 for
ﬁve days. Tissue culture supernatants were collected and
analyzed for the production of 42 cytokines using Luminex
technology. Three patients responded to treatment with ECP
and three did not and later received other therapies. We have
previously reported that responding patients had higher
CD4+CD25+FoxP3+ cells. Of the cytokines analyzed, soluble
CD25 and TNFbwere secreted at signiﬁcantly higher levels in
responding patients prior to ECP initiating therapy (Figure).
In responders, sCD25 and TNFb levels remained high
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did not show signiﬁcant trend between responders and non
responders. Thus, sCD25 and TNFb can be potentially used as
biomarkers to predict response of cGvHD to ECP. Studies with
larger number of patients on ECP will be required to conﬁrm
these ﬁndings.429
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The cGVHD Symptom Bother Scale, known as the Lee cGVHD
scale, is a patient reported questionnaire developed and
validated in English to measure symptoms and functional
losses in patients (pts.) with cGVHD. The Lee cGVHD scale
includes 30 questions with 7 subscales containing 2 to 7
items representing domains of skin, mouth, respiratory
system, gastrointestinal system, energy and psychological
status. The Lee cGVHD scale was translated into Portuguese
and validated according to the American Association of
Orthopedic Surgeons Outcome Committee guideline. 47 adult
pts with cGVHD diagnosed according to the 2005 NIH
consensus criteria were studied by the Brazil-Seattle cGVHD
Consortium between 2011 to 2012 at 5 centers. Median age
was 48 years (23-69) and 29 (61.7%) were male. All pts.
completed the Brazilian version of the Lee cGVHD ques-
tionnaire, the Medical Outcomes Study Short Form 36 (SF-
36) and the Functional Assessment of Chronic Illness Therapy
with Bone Marrow Transplant subscale (FACT-BMT). Overall
cGVHD severity was also assessed by pt. (0-3 scale) and by
physician (0-10 scale). Reliability was assessed using Cron-
bach's alpha and intraclass correlation coefﬁcients. Spear-
man's correlation coefﬁcient was used to measure constructOther Evaluations
Lee chronic GVHD Scale (0-100)y
Energy Skin Nutrition
SF-36
Physical Summary -0.49* -0.41* -0.43*
Emotional Summary -0.54* -0.32* -0.34*
FACT-BMT Summary 0.48* 0.40* 0.34*
GVHD severity rated by:
Physician 0.17 0.27 0.45*
Patient -0.04 0.15 0.25
* Correlation is signiﬁcant at the 0.05 level (2-tailed)
y Numbers represent Spearman’s correlation coefﬁcient: Very Low: 0.0< r  0.2validity. Results showed the reliability of the Lee cGVHD scale
was satisfactory (Cronbach's alpha 0.62-0.83). Correlation
coefﬁcients were moderate between similar domains of the
Lee cGVHD scale, SF-36, FACT-BMT and overall cGVHD
severity as rated by the physician but, correlation was low
between Lee cGVHD scale and overall cGVHD severity
assessed by patient (Table). The Brazilian Portuguese version
of the Lee cGVHD scale is reliable and easy to apply but
a larger cohort is needed to validate the instrument in this
population.430
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Background: Allogeneic hematopoietic stem cell trans-
plantation is a curative treatment for a number of hemato-
logical malignancies. Graft-versus-host disease (GVHD)
remains a leading cause of morbidity and mortality. Rabbit
anti-thymocyte globulin (ATG) is used to reduce the inci-
dence of GVHD. However, dosing regimens and schedules
vary.
Methods:We reviewed the medical records of 88 patients at
our institutionwho received ATG at either 4.5 or 6.0mg/kg, in
combination with tacrolimus and mycophenolate, prior to
allogeneic stem cell transplantation between 2009 and 2011.
ATG was administered over 3 days, ﬁnishing on day 0. We
retrospectively evaluated the prophylactic effect of each ATG
dosing regimen by measuring the incidence of severe (grade
III-IV) acute GVHD and acute GVHD-associated mortality. We
also measured relapse rate, overall survival (OS) and
progression-free survival (PFS) for both groups.
Results: A total of 52 patients who received ATG at 4.5mg/kg
(ATG1) were comparedwith 36 patients who received ATG at
6.0mg/kg (ATG2). The degree of HLA-mismatching was
greater in ATG2 (39.1% mismatched unrelated donors) as
compared to ATG1 (10% mismatched unrelated donors)
(P¼0.019) among 53 recipients from unrelated donors.
Median follow up for ATG1was 362 days, as compared to 512
days for ATG2. The cumulative incidence of grade III-IV acute
GVHD at day 100 was 13.9% and 6.5% in the ATG1 and ATG2
groups, respectively (P¼0.256). Speciﬁcally, 6 patients in
ATG1 developed grade IV GHVD, as compared to 0 patients in
ATG2. Acute GVHD-associated mortality was 7.7% and 0% in
ATG1 and ATG2, respectively (P¼0.141). All GVHD-associated
deaths occurred in patients with grade IV GVHD. The relapse
rates were comparable between ATG1 and ATG2 for bothLung Psych Eye Mouth Summary
-0.32* -0.51* -0.26 -0.35* -0.66*
-0.31* -0.70* -0.25 -0.27 -0.63*
0.18 0.49* 0.01 0.42* 0.48*
0.11 0.20 0.44* 0.27 0.51*
-0.07 0.06 27 0.21 0.25
, Low. 0.2 < r  0.4, Moderate 0.4 < r  0.6, High 0.6 < r
